Antimyeloma activity of the sesquiterpene lactone cnicin: Impact on Pim-2 kinase as a novel therapeutic target

Journal of Molecular Medicine

Volumn 90, Issue 6, 2012, Pages 681-693

  Jöhrer, Karin ^a   Obkircher, Marlene ^a   Neureiter, Daniel ^b   Parteli, Johanna ^a   Zelle Rieser, Claudia ^a   Maizner, Eva ^a   Kern, Johann ^c   Hermann, Martin ^c   Hamacher, Frank ^d   Merkel, Olaf ^d   Wacht, Nathalie ^d   Zidorn, Christian ^e   Scheideler, Marcel ^f   Greil, Richard ^a,d  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d St Johanns Spital   (Austria)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Cnicin; Multiple myeloma; Pim 2; Sesquiterpene lactone

Indexed keywords

ANTINEOPLASTIC AGENT; CNICIN; PHOSPHOTRANSFERASE; PIM 2 KINASE; SESQUITERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MYELOMA CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SESQUITERPENES;

EID: 84862687198     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0848-x     Document Type: Article

References (46)

1. T Hideshima D Chauhan P Richardson C Mitsiades N Mitsiades T Hayashi N Munshi L Dang A Castro V Palombella, et al. 2002 NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 16639 16647 11872748 10.1074/jbc.M200360200 1:CAS:528:DC%2BD38XjslWhtrw%3D
2. K Kawauchi T Ogasawara M Yasuyama K Otsuka O Yamada 2009 The PI3K/Akt pathway as a target in the treatment of hematologic malignancies Anticancer Agents Med Chem 9 550 559 19519296 1:CAS:528:DC%2BD1MXos1als70%3D
3. T Hideshima M Akiyama T Hayashi P Richardson R Schlossman D Chauhan KC Anderson 2003 Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu Blood 101 703 705 12393542 10.1182/blood-2002-06-1874 1:CAS:528:DC%2BD3sXkvVajsQ%3D%3D
4. DJ Newman GM Cragg 2007 Natural products as sources of new drugs over the last 25 years J Nat Prod 70 461 477 17309302 10.1021/np068054v 1:CAS:528:DC%2BD2sXhvFKrsro%3D
5. M Bruno S Rosselli A Maggio RA Raccuglia KF Bastow CC Wu KH Lee 2005 Cytotoxic activity of some natural and synthetic sesquiterpene lactones Planta Med 71 1176 1178 16395659 10.1055/s-2005-873139 1:CAS:528:DC%2BD28XotFGjtA%3D%3D
6. JY Hung YL Hsu WC Ni YM Tsai CJ Yang PL Kuo MS Huang 2010 Oxidative and endoplasmic reticulum stress signaling are involved in dehydrocostuslactone- mediated apoptosis in human non-small cell lung cancer cells Lung Cancer 68 355 365 19700217 10.1016/j.lungcan.2009.07.017
7. H Ichikawa MS Nair Y Takada DB Sheeja MA Kumar OV Oommen BB Aggarwal 2006 Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappaB (nf-kappaB) activation and nf-kappaB-regulated gene expression Clin Cancer Res 12 5910 5918 17021000 10.1158/1078-0432.CCR-06-0916 1:CAS:528:DC%2BD28XhtVartbnJ
8. J Lee C Hwangbo JJ Lee J Seo JH Lee 2010 The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression Oncol Rep 23 229 237 19956887 1:CAS:528:DC%2BC3cXoslGntg%3D%3D
9. K Lesiak K Koprowska I Zalesna D Nejc M Duchler M Czyz 2010 Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro Melanoma Res 20 21 34 19949351 10.1097/CMR.0b013e328333bbe4 1:CAS:528:DC%2BC3cXhtFygtw%3D%3D
10. V Saroglou A Karioti C Demetzos K Dimas H Skaltsa 2005 Sesquiterpene lactones from Centaurea spinosa and their antibacterial and cytotoxic activities J Nat Prod 68 1404 1407 16180824 10.1021/np058042u 1:CAS:528: DC%2BD2MXosVWlsL8%3D
11. AJ Steele DT Jones K Ganeshaguru VM Duke BC Yogashangary JM North MW Lowdell PD Kottaridis AB Mehta AG Prentice, et al. 2006 The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro Leukemia 20 1073 1079 16628188 10.1038/sj.leu.2404230 1:CAS:528:DC%2BD28XkvVymu7g%3D
12. A Suvannasankha CD Crean R Shanmugam SS Farag R Abonour HS Boswell H Nakshatri 2008 Antimyeloma effects of a sesquiterpene lactone parthenolide Clin Cancer Res 14 1814 1822 18347184 10.1158/1078-0432.CCR-07-1359 1:CAS:528:DC%2BD1cXjtleju7s%3D
13. W Wang M Adachi R Kawamura H Sakamoto T Hayashi T Ishida K Imai Y Shinomura 2006 Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity Apoptosis 11 2225 2235 17051330 10.1007/s10495-006-0287-2 1:CAS:528:DC%2BD28Xht1KmtrfF
14. R Vanhaelen-Fastre M Vanhaelen 1976 Antibiotic and cytotoxic activity of cnicin and of its hydrolysis products. Chemical structure-biological activity relationship Planta Med 29 179 189 948519 10.1055/s-0028-1097650 1:CAS:528:DyaE28XhslCnsLk%3D (author's transl)
15. G Schneider I Lachner 1987 Analysis and action of cnicin Planta Med 53 247 251 3628557 10.1055/s-2006-962693 1:CAS:528:DyaL2sXlvFSmtr0%3D
16. RT Woodland CJ Fox MR Schmidt PS Hammerman JT Opferman SJ Korsmeyer DM Hilbert CB Thompson 2008 Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival Blood 111 750 760 17942753 10.1182/blood-2007-03-077222 1:CAS:528:DC%2BD1cXns1Cmug%3D%3D
17. AM Cohen B Grinblat H Bessler D Kristt A Kremer A Schwartz M Halperin S Shalom D Merkel J Don 2004 Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma Leuk Lymphoma 45 951 955 15291354 10.1080/10428190310001641251 1:CAS:528:DC%2BD2cXjtFOjsbk%3D
18. JO Claudio E Masih-Khan H Tang J Goncalves M Voralia ZH Li V Nadeem E Cukerman O Francisco-Pabalan CC Liew, et al. 2002 A molecular compendium of genes expressed in multiple myeloma Blood 100 2175 2186 12200383 10.1182/blood-2002-01-0008 1:CAS:528:DC%2BD38Xnt1yhsLY%3D
19. J Asano A Nakano A Oda H Amou M Hiasa K Takeuchi H Miki S Nakamura T Harada S Fujii, et al. 2011 The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells Leukemia 25 1182 1188 21475253 10.1038/leu.2011.60 1:CAS:528:DC%2BC3MXoslOitbk%3D
20. CJ Fox PS Hammerman RM Cinalli SR Master LA Chodosh CB Thompson 2003 The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor Genes Dev 17 1841 1854 12869584 10.1101/gad.1105003 1:CAS:528:DC%2BD3sXmt1Sjtrc%3D
21. R Amson F Sigaux S Przedborski G Flandrin D Givol A Telerman 1989 The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias Proc Natl Acad Sci U S A 86 8857 8861 2682662 10.1073/pnas.86.22.8857 1:CAS:528:DyaK3cXkvFOlsw%3D%3D
22. CJ Fox PS Hammerman CB Thompson 2005 The Pim kinases control rapamycin-resistant T cell survival and activation J Exp Med 201 259 266 15642745 10.1084/jem.20042020 1:CAS:528:DC%2BD2MXot12muw%3D%3D
23. PS Hammerman CJ Fox MJ Birnbaum CB Thompson 2005 Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival Blood 105 4477 4483 15705789 10.1182/blood-2004-09-3706 1:CAS:528:DC%2BD2MXks12isb8%3D
24. JL Chen A Limnander PB Rothman 2008 Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene Blood 111 1677 1685 18042805 10.1182/blood-2007-04-083808 1:CAS:528:DC%2BD1cXhvFeisrk%3D
25. JD Allen E Verhoeven J Domen M van der Valk A Berns 1997 Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc Oncogene 15 1133 1141 9294606 10.1038/sj.onc.1201288 1:CAS:528:DyaK2sXmt1Gju78%3D
26. Y Zhang Z Wang X Li NS Magnuson 2008 Pim kinase-dependent inhibition of c-Myc degradation Oncogene 27 4809 4819 18438430 10.1038/onc.2008.123 1:CAS:528:DC%2BD1cXpvVSqtb4%3D
27. ML Breuer HT Cuypers A Berns 1989 Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas EMBO J 8 743 748 2721500 1:CAS:528:DyaL1MXhvVOis7o%3D
28. JH Schatz E Oricchio AL Wolfe M Jiang I Linkov J Maragulia W Shi Z Zhang VK Rajasekhar NC Pagano JA Porco Jr J Teruya-Feldstein N Rosen AD Zelenetz J Pelletier HG Wendel 2011 J Exp Med 208 1799 1807 21859846 10.1084/jem.20110846 1:CAS:528:DC%2BC3MXhtFeqsbbL
29. S Greenstein NL Krett Y Kurosawa C Ma D Chauhan T Hideshima KC Anderson ST Rosen 2003 Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells Exp Hematol 31 271 282 12691914 10.1016/S0301-472X(03)00023-7 1:CAS:528:DC%2BD3sXislChtrw%3D
30. PM Rood J Calafat AE von dem Borne WR Gerritsen CE van der Schoot 2000 Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines Eur J Clin Invest 30 618 629 10886302 10.1046/j.1365-2362.2000.00672. x 1:STN:280:DC%2BD3cvjs1aktA%3D%3D
31. EI Deryugina JP Quigley 2008 Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules Methods Enzymol 444 21 41 19007659 10.1016/S0076-6879(08)02802-4 1:CAS:528:DC%2BD1cXhsVartrzM
32. B Kulterer G Friedl A Jandrositz F Sanchez-Cabo A Prokesch C Paar M Scheideler R Windhager KH Preisegger Z Trajanoski 2007 Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation BMC Genomics 8 70 76 17352823 10.1186/1471-2164-8-70
33. EJ Choi WS Ahn 2009 Antiproliferative effects of dehydrocostuslactone through cell cycle arrest and apoptosis in human ovarian cancer SK-OV-3 cells Int J Mol Med 23 211 216 19148545 10.3892/ijmm-00000177 1:CAS:528: DC%2BD1MXisVGitL4%3D
34. K Kunzi-Rapp F Genze R Kufer E Reich RE Hautmann JE Gschwend 2001 Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model J Urol 166 1502 1507 11547121 10.1016/S0022-5347(05)65820-X 1:STN:280:DC%2BD3MvpvVeguw%3D%3D
35. CL Saw PW Heng CV Liew 2008 Chick chorioallantoic membrane as an in situ biological membrane for pharmaceutical formulation development: a review Drug Dev Ind Pharm 34 1168 1177 18663656 10.1080/03639040801974295 1:CAS:528:DC%2BD1cXht1KrsbnE
36. M Taizi VR Deutsch A Leitner A Ohana RS Goldstein 2006 A novel and rapid in vivo system for testing therapeutics on human leukemias Exp Hematol 34 1698 1708 17157167 10.1016/j.exphem.2006.07.005 1:CAS:528:DC%2BD28Xht12qsrjI
37. J Parada-Turska R Paduch M Majdan M Kandefer.Szerszen W Rzeski 2007 Antiproliferative activity of parthenolide against three human cancer cell lines and umbilical vein endothelial cells Pharmacol Rep 59 233 237 17556802 1:CAS:528:DC%2BD2sXhtVCqsLjE
38. SJ Zunino DH Storms JM Ducore 2010 Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11) Int J Oncol 37 1307 1313 20878078 10.3892/ijo-00000782 1:CAS:528:DC%2BC3cXhsVegsb3J
39. JS Clerkin R Naughton C Quiney TG Cotter 2008 Mechanisms of ROS modulated cell survival during carcinogenesis Cancer Lett 266 30 36 18372105 10.1016/j.canlet.2008.02.029 1:CAS:528:DC%2BD1cXmsFKlu7c%3D
40. R Amaravadi CB Thompson 2005 The survival kinases Akt and Pim as potential pharmacological targets J Clin Invest 115 2618 2624 16200194 10.1172/JCI26273 1:CAS:528:DC%2BD2MXhtVygt7vL
41. A Zollinger T Stuhmer M Chatterjee S Gattenlohner E Haralambieva HK Muller-Hermelink M Andrulis A Greiner C Wesemeier JC Rath, et al. 2008 Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma Blood 112 3403 3411 18635812 10.1182/blood-2007-11-119362
42. H Dai R Li T Wheeler DV Diaz A Frolov S Tahir I Agoulnik T Thompson D Rowley G Ayala 2005 Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer Prostate 65 276 286 16015593 10.1002/pros.20294 1:CAS:528:DC%2BD2MXht1SisLfP
43. JW Behan JP Yun MP Proektor EA Ehsanipour A Arutyunyan AS Moses VI Avramis SG Louie A Butturini N Heisterkamp, et al. 2009 Adipocytes impair leukemia treatment in mice Cancer Res 69 7867 7874 19773440 10.1158/0008-5472. CAN-09-0800 1:CAS:528:DC%2BD1MXht1Skt7bI
44. A Ghantous H Gali-Muhtasib H Vuorela NA Saliba N Darwiche 2010 What made sesquiterpene lactones reach clinical trials? Drug Discov Today 15 668 678 20541036 10.1016/j.drudis.2010.06.002 1:CAS:528:DC%2BC3cXhtVeksb3K
45. I Merfort 2011 Perspectives on sesquiterpene actones in inflammation and cancer Curr Drug Targets 12 1560 1573 21561425 10.2174/138945011798109437 1:CAS:528:DC%2BC3MXht1Omt77F
46. EA Curry 3rd DJ Murry C Yoder K Fife V Armstrong H Nakshatri M O'Connell CJ Sweeney 2004 Invest New Drugs 22 299 305 15122077 10.1023/B:DRUG.0000026256. 38560.be 1:CAS:528:DC%2BD2cXjsF2isrg%3D